1114 related articles for article (PubMed ID: 17430582)
21. Hormone receptor status and mitotic activity as risk factors for recurrence and death in female breast carcinoma.
Aaltomaa S; Lipponen P; Eskelinen M; Kosma VM; Marin S; Alhava E; Syrjänen K
Anticancer Res; 1991; 11(5):1701-6. PubMed ID: 1768039
[TBL] [Abstract][Full Text] [Related]
22. Alternative therapy for elderly patients with breast cancer.
von Rueden DG; Sessions SC
Am Surg; 1994 Jan; 60(1):72-8. PubMed ID: 8273979
[TBL] [Abstract][Full Text] [Related]
23. Sex steroid receptors, S-phase fraction and DNA ploidy as determinants of the risk of relapse and death of female breast cancer.
Lipponen P; Eskelinen M; Papinaho S; Klemi PJ; Aaltomaa S; Kosma VM; Marin S; Syrjänen K
Anticancer Res; 1992; 12(3):677-82. PubMed ID: 1622125
[TBL] [Abstract][Full Text] [Related]
24. [The role of radiotherapy in the multimodal treatment of locally advanced breast carcinoma].
Guenzi M; Scarpati D; Corvò R; Sanguineti G; Gardin G; Conte PF; Vitale V
Radiol Med; 1990 May; 79(5):534-8. PubMed ID: 2359862
[TBL] [Abstract][Full Text] [Related]
25. Bcl-2 protein expression and long-term survival in breast cancer.
Joensuu H; Pylkkänen L; Toikkanen S
Am J Pathol; 1994 Nov; 145(5):1191-8. PubMed ID: 7977649
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of immunohistochemical c-erbB-2 proto-oncogene expression and nuclear DNA content in human breast cancer.
Schimmelpenning H; Eriksson ET; Falkmer UG; Rutqvist LE; Johansson H; Fallenius A; Auer GU
Eur J Surg Oncol; 1992 Dec; 18(6):530-7. PubMed ID: 1362164
[TBL] [Abstract][Full Text] [Related]
27. Comparison of partial and modified radical mastectomy in the community setting--"10 years later".
Kuusk U; Basco V; Rebbeck P
Can J Surg; 1992 Aug; 35(4):383-7. PubMed ID: 1323380
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significances of estrogen and progesterone receptors in primary operable breast cancer.
Kurebayashi J; Ishida T; Higashi Y; Suemasu K; Nomoto C; Yoshida K
Jpn J Clin Oncol; 1990 Sep; 20(3):271-80. PubMed ID: 2255103
[TBL] [Abstract][Full Text] [Related]
29. Systemic therapy in node-negative patients: updated findings from NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project.
Fisher B; Redmond C
J Natl Cancer Inst Monogr; 1992; (11):105-16. PubMed ID: 1627417
[TBL] [Abstract][Full Text] [Related]
30. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome.
Sataloff DM; Mason BA; Prestipino AJ; Seinige UL; Lieber CP; Baloch Z
J Am Coll Surg; 1995 Mar; 180(3):297-306. PubMed ID: 7874340
[TBL] [Abstract][Full Text] [Related]
31. [What are the prognostic factors in operable breast cancer without histologic axillary lymph node invasiveness. Results of an uni- and multifactorial analysis].
Chevallier B; Heintzman F; Mosseri V; Graic Y; Bastit P; Dauce JP; Maisse P; Cauchois D; Cabanne JP; Asselain B
Bull Cancer; 1989; 76(1):51-60. PubMed ID: 2713515
[TBL] [Abstract][Full Text] [Related]
32. [Cancer of the breast and the receptor status].
Buonomo O; Serao A; Muggianu A; Guglielmelli E; Davoli E; Amori A
G Chir; 1991 Apr; 12(4):274-7. PubMed ID: 1911078
[TBL] [Abstract][Full Text] [Related]
33. [Follow-up of 551 patients with node-negative breast cancer].
Eidtmann H; Jonat W; Lange C; Friedrichs K; Maass H
Geburtshilfe Frauenheilkd; 1992 Aug; 52(8):454-61. PubMed ID: 1397940
[TBL] [Abstract][Full Text] [Related]
34. [Flow cytometry detected S-phase fraction and ploidy as prognostic parameters in primary, node-negative breast cancer].
Winter K; Eidtmann H; Jonat W
Geburtshilfe Frauenheilkd; 1994 May; 54(5):291-4. PubMed ID: 8050690
[TBL] [Abstract][Full Text] [Related]
35. [A randomized clinical trial of adjuvant endocrine therapy after breast conserving surgery for early breast cancer. Cooperative Study Group for Breast Conserving Therapy].
Nakamura Y; Tominaga T; Nomura Y; Koyama H; Miura S; Morimoto T
Gan To Kagaku Ryoho; 1994 Jun; 21 Suppl 2():217-25. PubMed ID: 8037485
[TBL] [Abstract][Full Text] [Related]
36. [The value of the "vascular invasion" factor for prognosis of breast cancer].
Kurz C; Obermair A; Nagele F; Czerwenka K; Schemper M; Kubista E; Sevelda P
Geburtshilfe Frauenheilkd; 1994 May; 54(5):295-9. PubMed ID: 8050691
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of cathepsin-D expression in female breast cancer.
Aaltonen M; Lipponen P; Kosma VM; Aaltomaa S; Syrjänen K
Anticancer Res; 1995; 15(3):1033-7. PubMed ID: 7645922
[TBL] [Abstract][Full Text] [Related]
38. [Reevaluation of indications for adjuvant hormone therapy in primary breast cancer with high metastatic risk].
Martin PM; Romain S; Spyratos F; Spitalier JM; Ayme Y; Brandone H; Bressac C; Hans D; Jacquemier J; Hacene K
Bull Cancer; 1991; 78(8):709-23. PubMed ID: 1932838
[TBL] [Abstract][Full Text] [Related]
39. Prediction of recurrence for advanced breast cancer. Traditional and contemporary pathologic and molecular markers.
Masood S
Surg Oncol Clin N Am; 1995 Oct; 4(4):601-32. PubMed ID: 8535901
[TBL] [Abstract][Full Text] [Related]
40. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis.
Lipponen P; Pietiläinen T; Kosma VM; Aaltomaa S; Eskelinen M; Syrjänen K
J Pathol; 1995 Sep; 177(1):49-55. PubMed ID: 7472779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
